Q&A session 3 for paid subscribers

Will the ATARA-Bio's trial of ATA188 be positive? Does rituximab get into the CNS and kill EBV-infected B-cells? Are sebaceous cysts and rosacea associated with MS?

Questions

Q1: Do you expect the ATARA-Bio trial of ATA188, targeting EBV, to be positive?

Q2: Since rituximab does not cross the blood-brain barrier. How is it able to effect change within the CNS and stop progression? Is killing peripheral B cells enough to stop virus-infected B cells in the CNS from replicating and thus progressing MS?

Q3: I am a female, aged 32. A few years before my MS diagnosis in 2021, I developed facial sebaceous cysts and rosacea - both conditions persist to this day, with the facial sebaceous cysts tending to be more sporadic, the rosacea is pretty much a constant. Are these conditions possibly linked to my MS, and if so, could they benefit from some targeted treatment approach? I've been on fingolimod (Gilenya) since my MS diagnosis in 2021.

NOTE: General substack newsletters and the microsite are free; only these Q&A sessions are restricted to paying subscribers. I can't run and maintain the MS-Selfie microsite, hence the need to hire people to help do the work for me. If people want to ask medical and other questions unrelated to the free Newsletters or Podcasts, they must become paying subscribers. If you can’t afford to become a paying subscriber and want access to the Q&A sessions, please email to request a complimentary subscription.

Email - ms-selfie@giovannoni.net